# Astraveus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/astraveus

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.astraveus.com
- Total disclosed funding: $18M
- Latest round: Seed (Jun 27, 2023)
- Investors on record: 4

## About

Based in Paris, France, and founded in 2016 by CEO Jeremie Lauren, Astraveus SAS operates as a biotechnology company that develops a microfluidic cell foundry that facilitates the creation and production of the majority of cell and gene therapies. In June 2023, Astraveus SAS raised EUR 16.5 million in seed funding led by AdBio Partners, with participation from other CDC Enterprises, Johnson & Johnson Innovation, and M Ventures. In October 2023, Astraveus SAS received EUR 10.4 million in grant funding frominvestor Government of France.

Astraveus offers a CGT (cell and gene therapy) manufacturing platform, Lakhesys, used to optimize and miniaturize cellular therapies. The company’s platform uses microfluidic bioprocessors to miniaturize and automate cell and gene therapy manufacturing, which includes CAR-T cells and hematopoietic stem cells (HSCs) that produce blood cells.

The company plans to use the October 2023 funding to further develop its Lakhesys platform.

## Funding rounds

- Seed, Jun 27, 2023, $18M — Johnson & Johnson Innovation, Bpifrance, AdBio Partners, M Ventures

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Seed
- Bpifrance — Seed
- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Seed
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Seed